

PTO/SB/088 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/734,149		
		Filing Date	December 15, 2003		
		First Named Inventor	JULIUS, Michael H.		
		Art Unit			
		Examiner Name			
Sheet	2	of	3	Attorney Docket Number	32388-2038


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
MB		ZHOU et al. PNAS (1998) 95:2492-7	
		IKEDA, A. et al., "Molecular Cloning of Bovine CD 14 Gene", Journal of Veterinary Medical Science-Nihon Juigaku Zasshi, JP, Japanese Society of Veterinary Science vol. 59, No. 8 <u>pages 715-719, 1997</u>	
		JABARA, H.H. et al., "Engagement of CD 14 on Monocytes Inhibits the Synthesis of Human Lgs., including 1gE", The Journal of Immunology, vol. 153, pp. 972-978, 1994	
		JUAN, Todd S.-C. et al., "Soluble CD 14 Truncated at Amino Acid 152 Binds Lipopolysaccharide (LPS) and Enables Cellular Responses to LPS", The Journal of Biological Chemistry, <u>1996, V 53, pages 241-247</u>	
		JULIUS, M.H. et al., "A Colostral Protein that Induces the Growth and Differentiation of Resting B.Lymphocytes", The Journal of Immunology, vol. 140, No. 5, pp. 1366-1371, <u>1998</u>	
		LOMS, Ziegler-Heitbrock, H.W. et al., "CD14 is Expressed and Functional in Human B Cells", European Journal of Immunology, vol. 24, No. 8, pp. 1937-1940, 1994	
		FILIPP, D. et al., "Soluble DC14 Enriched in Colostrum and Milk Induces B Cell Growth and Differentiation", Proceedings of the National Academy of Sciences, vol. 98, No. 2, <u>2001</u>	
		SETOGUCHI, M. et al., "Mouse and Human CD14 (Myeloid Cell-Specific Leucine-Rich Glycoprotein) Primary Structure Deduced from CDNA Clones", Biochemica et Bio-physica Acta. Gene, <u>1983 V 2, pages 213-222</u>	
		SIMMONS, D. L. et al., "Monocyte Antigen CD14 is a Phospholipid Anchored Membrane Protein", Blood; vol. 73, No. 1, 1989, pp. 284-289	
MB		Ulevitch, R.J. et al., "Receptor-Dependent Mechanisms of Cell Stimulation by Bacterial Endotoxin", Annual Review of Immunology, U.S., Annual Reviews, Inc. <u>1995, V 13, pp 437-457</u>	

Examiner Signature		Date Considered	7/25/05
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/734,149
		Filing Date	December 15, 2003
		First Named Inventor	JULIUS, Michael H.
		Art Unit	
		Examiner Name	
Sheet 3	of 3	Attorney Docket Number	32388-2038

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
MUS		VIRIYAKOSOL, et al., "The N-terminal Half of Membrane CD14 is a Functional Cellular Lipopolysaccharide Receptor", Infection and Immunity, vol. 64, pp 653-656, 1996	
		WANG Y. et al., "Detection and Identification of Soluble CD14 in Bovine Milk", Molecular Biology of The Cell, vol. 8, 1997, No. 5. p. 85A XP002062360	
		YANG Z. et al., "Analysis of the CD14 Receptor Associated with Bovine Alveolar Macrophages", Inflammation, vol. 20, No. 1, pp. 97-106, Feb 1996	
M/S		YANG Z. et al., "Soluble CD14 and Lipopolysaccharide-Binding Protein from Bovine Serum Enable Bacterial Lipopolysaccharide-Mediated Cytotoxicity and Activation of Bovine Vascular Endothelial Cells", J. of Leukocyte Biol. 1996, Vol. 59, pp 241-247	

Examiner Signature		Date Considered	7/25/05
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.